Table 1.
Baseline Clinical and Pathologic Characteristics of Prostate Cancer Patients Diagnosed in the HPFS Cohort From July 1986 to May 2007
| Characteristic | Total (N = 3,331)* | Deferred Treatment (n = 342) | Any Treatment (n = 2,989)* | P† |
|---|---|---|---|---|
| Mean follow-up time, years | 8.6 | 8.3 | 8.6 | .24 |
| Age at diagnosis, years | ||||
| Mean | 68.4 | 72.7 | 67.9 | < .0001 |
| < 50 | 0.5 | 0 | 0.5 | < .0001 |
| 50-59 | 12.8 | 5.9 | 13.6 | |
| 60-69 | 44.6 | 27.8 | 46.5 | |
| 70-79 | 37.8 | 52.1 | 36.1 | |
| 80+ | 4.4 | 14.3 | 3.3 | |
| Race | ||||
| White | 96.7 | 95.7 | 96.9 | .25 |
| Black | 0.9 | 1.8 | 0.8 | |
| Asian | 1.1 | 1.2 | 1.1 | |
| Other | 1.3 | 1.2 | 1.3 | |
| Mean height, inches | 70.1 | 69.7 | 70.1 | .006 |
| BMI | ||||
| < 21 | 4.0 | 4.7 | 3.9 | .25 |
| 21 to < 25 | 39.5 | 42.9 | 39.1 | |
| 25 to < 30 | 46.0 | 44.5 | 46.2 | |
| 30+ | 10.5 | 7.9 | 10.8 | |
| Stage | ||||
| T1 | 51.7 | 63.2 | 50.5 | < .0001 |
| T2 | 41.4 | 34.1 | 42.2 | |
| T3 | 5.3 | 2.3 | 5.6 | |
| T4 | 0 | 0 | 0 | |
| N1/M1 | 1.6 | 0.3 | 1.7 | |
| PSA at diagnosis, ng/mL | ||||
| Median | 7.0 | 6.7 | 7.0 | .10 |
| < 4 | 11.8 | 16.5 | 11.3 | .04 |
| 4 to < 10 | 58.8 | 53.7 | 59.3 | |
| 10-20 | 20.0 | 21.7 | 19.8 | |
| > 20 | 9.4 | 8.1 | 9.6 | |
| Biopsy Gleason score | ||||
| < 6 | 21.2 | 28.9 | 20.4 | .002 |
| 6 | 45.6 | 46.9 | 45.5 | |
| 7 | 25.0 | 17.2 | 25.8 | |
| 8+ | 8.2 | 7.0 | 8.3 |
NOTE. Tabulated values are percentages unless otherwise indicated. The analysis does not include 279 participants whose treatment information was unavailable to determine initial cancer case status (eg, deferred treatment v active treatment).
Abbreviations: HPFS, Health Professionals Follow-up Study; BMI, body mass index; PSA, prostate-specific antigen.
Of the 2,989 participants who received immediate treatment, 1,599 had a radical prostatectomy, 549 had external radiotherapy monotherapy, 239 had brachytherapy monotherapy, 368 had androgen deprivation therapy plus external radiotherapy or brachytherapy, 181 had androgen deprivation monotherapy, and 53 had other types of treatment.
Deferred treatment v any treatment.